Pulmonary osteoclast-like cells in silica induced pulmonary fibrosis
Yoshihiro Hasegawa,Jennifer M Franks,Yusuke Tanaka,Yasuaki Uehara,David F Read,Claire Williams,Sanjay Srivatsan,Lori B Pitstick,Nikolaos M Nikolaidis,Ciara M Shaver,Jonathan Kropski,Lorraine B Ware,Chase J Taylor,Nicholas E Banovich,Huixing Wu,Jason C Gardner,Andrew R Osterburg,Jane J Yu,Elizabeth J Kopras,Steven L Teitelbaum,Kathryn A Wikenheiser-Brokamp,Cole Trapnell,Francis X McCormack
DOI: https://doi.org/10.1126/sciadv.adl4913
2024-07-12
Abstract:The pathophysiology of silicosis is poorly understood, limiting development of therapies for those who have been exposed to the respirable particle. We explored mechanisms of silica-induced pulmonary fibrosis in human lung samples collected from patients with occupational exposure to silica and in a longitudinal mouse model of silicosis using multiple modalities including whole-lung single-cell RNA sequencing and histological, biochemical, and physiologic assessments. In addition to pulmonary inflammation and fibrosis, intratracheal silica challenge induced osteoclast-like differentiation of alveolar macrophages and recruited monocytes, driven by induction of the osteoclastogenic cytokine, receptor activator of nuclear factor κΒ ligand (RANKL) in pulmonary lymphocytes, and alveolar type II cells. Anti-RANKL monoclonal antibody treatment suppressed silica-induced osteoclast-like differentiation in the lung and attenuated pulmonary fibrosis. We conclude that silica induces differentiation of pulmonary osteoclast-like cells leading to progressive lung injury, likely due to sustained elaboration of bone-resorbing proteases and hydrochloric acid. Interrupting osteoclast-like differentiation may therefore constitute a promising avenue for moderating lung damage in silicosis.